MIF and neoplasm: We next verified whether ablating TAMCs or targeting the MIF‐mediated crosstalk among TAMCs, iCAFs, and T cells under the background of AG neoadjuvant therapy could ameliorate the suppressive TME and its pro‐tumor effects.